Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 13/20 | 0.46 |
| ▸ | SLC16A1 | P53985 | 13/20 | 0.46 |
| ▸ | MCTS1 | Q9ULC4 | 6/20 | 0.46 |
| ▸ | FYN | P06241 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29915480 | 0.88 | TP53 (0.44) | SLC16A3SLC16A1MCTS1MAPT | |
| SCHEMBL22613695 | 0.88 | SLC16A3 (0.51) | SLC16A3SLC16A1MCTS1FYNMAPT | |
| SCHEMBL29915303 | 0.85 | NPC1 (0.42) | SLC16A3SLC16A1MCTS1MAPTAKR1C3 | |
| SCHEMBL29915417 | 0.85 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1MAPT | |
| SCHEMBL29915357 | 0.85 | SLC16A3 (0.46) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29915423 | 0.85 | MAPT (0.46) | FYNMAPTAKR1C3 | |
| SCHEMBL29915313 | 0.81 | MAPT (0.40) | SLC16A3SLC16A1MCTS1MAPT | |
| SCHEMBL22613642 | 0.76 | SLC16A3 (0.49) | SLC16A3SLC16A1MCTS1MAPT | |
| SCHEMBL22613669 | 0.76 | SLC16A3 (0.52) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL29915428 | 0.74 | SLC16A3 (0.48) | SLC16A3SLC16A1MCTS1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | Recordati Industria Chimica e Farmacentica S.p.A. (IT) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440922-B2 | Heterocyclylmethylidene derivatives and their use as modulators of mGluR5 receptors | GRM5, GRIK5, GRM2 | SLC16A3 1146/4885SLC16A1 778/4885MCTS1 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.